CD8A and neoplasm: Immunization with MAN-OVA-IMNPs induced antigen-specific CD8+ T cells, greater lymphocyte activation, stronger cross-presentation, more generation of memory T cells, and more (Figure 5A), and when combined with the immune checkpoint blockade, further enhanced the anti-tumor effect [43].